Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

BUY
$0.27 - $0.5 $16,293 - $30,174
60,348 Added 3.57%
1,751,912 $491,000
Q1 2022

May 13, 2022

BUY
$0.37 - $0.54 $8,804 - $12,850
23,797 Added 1.43%
1,691,564 $778,000
Q4 2021

Feb 11, 2022

BUY
$0.34 - $0.86 $5,409 - $13,683
15,911 Added 0.96%
1,667,767 $853,000
Q1 2021

May 12, 2021

BUY
$0.68 - $1.25 $54,106 - $99,461
79,569 Added 5.06%
1,651,856 $1.14 Million
Q3 2020

Nov 13, 2020

SELL
$0.47 - $0.64 $539 - $734
-1,148 Reduced 0.07%
1,572,287 $743,000
Q2 2020

Aug 13, 2020

SELL
$0.41 - $0.73 $532,680 - $948,431
-1,299,221 Reduced 45.23%
1,573,435 $805,000
Q1 2020

May 14, 2020

BUY
$0.36 - $0.79 $51,840 - $113,760
144,000 Added 5.28%
2,872,656 $1.22 Million
Q4 2019

Feb 13, 2020

BUY
$0.75 - $0.89 $162,501 - $192,834
216,668 Added 8.63%
2,728,656 $2.13 Million
Q3 2019

Nov 12, 2019

SELL
$0.78 - $1.09 $293,571 - $410,247
-376,374 Reduced 13.03%
2,511,988 $2.28 Million
Q2 2019

Aug 14, 2019

BUY
$0.98 - $1.64 $441,829 - $739,387
450,846 Added 18.5%
2,888,362 $3.35 Million
Q1 2019

May 14, 2019

BUY
$0.67 - $1.01 $87,962 - $132,599
131,287 Added 5.69%
2,437,516 $2.39 Million
Q4 2018

Feb 13, 2019

SELL
$0.63 - $1.0 $6,997 - $11,107
-11,107 Reduced 0.48%
2,306,229 $1.63 Million
Q3 2018

Nov 13, 2018

SELL
$0.88 - $1.1 $139,968 - $174,960
-159,055 Reduced 6.42%
2,317,336 $2.31 Million
Q2 2018

Aug 14, 2018

BUY
$0.91 - $1.45 $1.33 Million - $2.12 Million
1,460,694 Added 143.81%
2,476,391 $2.4 Million
Q1 2018

May 15, 2018

BUY
$0.84 - $1.18 $147,772 - $207,585
175,920 Added 20.95%
1,015,697 $1.11 Million
Q2 2017

Aug 14, 2017

BUY
N/A
839,777
839,777 $361,000

Others Institutions Holding PTN

# of Institutions
1
Shares Held
2.94K
Call Options Held
0
Put Options Held
0

About PALATIN TECHNOLOGIES INC


  • Ticker PTN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,290,480
  • Market Cap $9.01M
  • Description
  • Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...
More about PTN
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.